{
    "pmcid": "9924070",
    "qa_pairs": {
        "How did the tetravalent format of the VHH72-Fc fusion compare to the bivalent format in terms of neutralization potency?": [
            "It demonstrated over 100-fold higher apparent affinity and significantly enhanced virus neutralizing activity",
            "It showed similar neutralization potency but improved pharmacokinetics",
            "It had reduced neutralization potency but increased stability",
            "It exhibited lower binding valency but higher specificity"
        ],
        "What is the primary target of the VHH72 nanobody in the SARS-CoV-2 spike protein?": [
            "A conserved epitope within the receptor-binding domain (RBD)",
            "The receptor-binding motif (RBM) within the spike protein",
            "The S2 subunit of the spike protein",
            "The N-terminal domain of the spike protein"
        ],
        "What modification was made to the Fc domain of VHH72 to minimize potential adverse effects?": [
            "LALA mutations to reduce Fc\u03b3 receptor binding",
            "S56A mutation to enhance binding affinity",
            "Fusion with a camelid IgG1 Fc domain",
            "Addition of a receptor-binding motif (RBM)"
        ],
        "What was the observed effect of VHH72-Fc constructs in animal models regarding SARS-CoV-2 infection?": [
            "They provided prophylactic and therapeutic protection, reducing viral replication in the lungs and other tissues",
            "They only provided prophylactic protection with no effect on viral replication",
            "They were ineffective in both prophylactic and therapeutic settings",
            "They increased viral replication in the lungs but reduced it in other tissues"
        ],
        "Which specific mutation was introduced to enhance the affinity of VHH72 for the SARS-CoV-2 RBD?": [
            "S56A",
            "F377A",
            "K378A",
            "LALA"
        ]
    }
}